A chance for longer life.
ERBITUX with radiation therapy (RT) may offer you the possibility.
ERBITUX with radiation therapy (RT) or RT alone was studied in a clinical study of 424 people with a certain type of
locally or regionally advanced head and neck cancer.
About half of the people (211) received ERBITUX with RT and the other half (213) were treated with RT alone.
The main goal of this clinical study was to assess the length of time people’s cancer did not grow or spread from where it started to nearby tissues or lymph nodes. An additional goal of the study was to measure how long people survived overall.
Results of the clinical study showed that combining ERBITUX with RT gave more people the opportunity for a longer life compared to RT alone.
Combining ERBITUX with radiation therapy (RT) may offer you a chance to live longer.
Half of the patients on ERBITUX with RT were still alive at 4.1 years compared to 2.4 years with RT alone, which is an improvement of about 1.6 years.
Median overall survival
45.6% of people who received ERBITUX with RT were alive 5 years after they started treatment compared to 36.4% of people treated with RT alone.
5-year survival rate
ERBITUX with radiation therapy (RT) may help keep your cancer under control longer
Half of the patients on ERBITUX with RT did not have their cancer grow or spread, come back, or die for 2.0 years compared to 1.2 years with RT alone (median duration of locoregional control).
Median duration of locoregional control
The safety and effectiveness for ERBITUX with RT are different for everyone. Individual results may vary. Your doctor is the best person to talk to about ERBITUX, what it may offer, and whether it’s the right option for you.
What is ERBITUX?
Epidermal growth factor receptor (EGFR) is a receptor found on both normal and tumor cells that is important for cell growth. ERBITUX is a type of drug, called an EGFR inhibitor, used to treat cancer by blocking the activity of EGFR. Blocking EGFR may keep cancer cells from growing.
- EGFR is present on some cancer cells, like colorectal cancer or head and neck cancer
- EGFR is also present on normal cells like skin, nail, or hair follicles
- Laboratory studies have shown that ERBITUX does not have an effect against tumor samples that do not have EGFR
How was ERBITUX shown to work?
In laboratory studies, ERBITUX was shown to:
- Block the signal: ERBITUX can block one of the signals that tells a tumor cell to grow by attaching to a structure on the cell called the EGFR. This structure is found on both normal cells and tumor cells
- Trigger an immune response: ERBITUX can form a bridge between a tumor cell and an immune cell when it is attached to the EGFR on the tumor cell. As a result, the immune cell can begin a response against the tumor cell
Want to know more about your treatment options and ERBITUX?
Your doctor and healthcare team can help answer your questions. Download a discussion guide with a list of questions to share at your next office visit.Questions to ask your doctor